Insider Transactions Reported by 19 Insiders of Prelude Therapeutics Inc

Symbol
PRLD on Nasdaq
Location
Wilmington, DE

Insiders trading volume in the past year

Prelude Therapeutics Inc executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
ORBIMED ADVISORS LLC Director, 10%+ Owner $38,151,480 22 May 2023
Krishna Vaddi CEO, Director $1,865,335 +$581,371 +45% 25 Mar 2025
Andrew Combs Chief Chemistry Officer $332,485 +$69,250 +26% 25 Mar 2025
Laurent Chardonnet Chief Financial Officer $158,962 01 Mar 2024
Jane Huang President, CMO $153,736 04 Oct 2025
Bryant D. Lim CLO, CFO, Corp Sec. $24,811 04 Feb 2025
Christopher Pierce EVP and Chief of Business Oper $14,138 02 Sep 2021
Deborah Morosini EVP, Chief of Clinical Affairs $1,674 15 Feb 2022
Martin Babler Director 12 Jun 2025
David J. Mauro Chief Medical Officer 05 Oct 2021
PAUL A. FRIEDMAN Director 12 Jun 2025
BAKER BROS. ADVISORS LP Director, 10%+ Owner 12 Jun 2025
Peggy Scherle Chief Scientific Officer 04 Feb 2025
David P. Bonita Director, 10%+ Owner 12 Jun 2025
Victor Sandor Director 05 Nov 2025
Paul C. Scherer Director 12 Jun 2025
Brian Piper Chief Financial Officer 25 Aug 2021
Katina Dorton Director 17 Oct 2025
Mardi Dier Director 12 Jun 2025

Recent Insider Transactions by Companies or Individuals for Prelude Therapeutics Inc

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.